
Annual report 2024
added 12-27-2025
Tiziana Life Sciences PLC EBITDA 2011-2025 | TLSA
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Tiziana Life Sciences PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -27.4 M | -28 M | -9.92 M | -9.87 M | -10.5 M | -7.28 M | -8.61 M | -2.76 M | -289 K | -263 K | -289 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -263 K | -28 M | -9.56 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Aclaris Therapeutics
ACRS
|
-141 M | $ 3.04 | 0.33 % | $ 235 M | ||
|
Aptevo Therapeutics
APVO
|
-24.2 M | $ 0.55 | -10.18 % | $ 152 K | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.09 | -2.68 % | $ 7.43 B | ||
|
Autolus Therapeutics plc
AUTL
|
-234 M | $ 1.8 | 7.9 % | $ 459 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 1.15 | 1.19 % | $ 6.27 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-11.4 M | - | 1.93 % | $ 17.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
BioVie
BIVI
|
-17.8 M | $ 1.22 | 1.05 % | $ 1.8 M | ||
|
AlloVir
ALVR
|
-200 M | - | 4.14 % | $ 49.1 M | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 209.89 | 0.44 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | ||
|
Athersys
ATHX
|
-85.6 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 0.18 | -14.31 % | $ 392 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-130 M | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
-89 M | - | -7.31 % | $ 87 M | ||
|
Catalyst Biosciences
CBIO
|
-66.2 M | $ 12.24 | -0.93 % | $ 806 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 94.79 | 0.29 % | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
234 M | $ 27.02 | -0.37 % | $ 1.31 B | ||
|
BeiGene, Ltd.
BGNE
|
-396 M | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | ||
|
Certara
CERT
|
263 K | $ 8.83 | -0.67 % | $ 1.42 B | ||
|
Anika Therapeutics
ANIK
|
-81.2 M | $ 9.57 | 0.21 % | $ 140 M | ||
|
bluebird bio
BLUE
|
-216 M | - | - | $ 546 M | ||
|
Arena Pharmaceuticals
ARNA
|
-620 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Cellectis S.A.
CLLS
|
-131 M | $ 4.91 | 3.37 % | $ 116 M | ||
|
Axon Enterprise
AXON
|
107 M | $ 580.12 | -0.64 % | $ 43.9 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-2.45 M | $ 2.47 | 0.82 % | $ 15.5 M | ||
|
ChromaDex Corporation
CDXC
|
8.39 M | - | -0.88 % | $ 598 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | $ 92.71 | -0.2 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
242 M | $ 9.21 | 1.27 % | $ 1.49 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
138 M | $ 81.86 | -0.96 % | $ 8.45 B |